EyePoint Pharmaceuticals Strategy and Business Model

Executive Overview

EyePoint is a U.S.-based ophthalmology biotechnology company focused on retinal disease. Founded in 1987 and now headquartered in Watertown, Massachusetts, the company has evolved from a small commercial ophthalmic-products business into a more concentrated clinical-stage retinal therapeutics company. Its strategic center of gravity is DURAVYU, formerly EYP-1901, an investigational sustained-delivery intravitreal treatment based on EyePoint’s drug-delivery technology and designed to reduce the frequency of injections for diseases such as wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). That matters because the retinal market is clinically important, economically attractive, and operationally specialized: products succeed not just on efficacy, but on durability, reimbursement fit, and retina-specialist adoption. EyePoint’s legacy approved products, including YUTIQ and DEXYCU, remain part of the company’s history and economics, but the business has increasingly shifted toward pipeline execution, clinical data, manufacturing readiness, and capital allocation. The company is operationally U.S.-centered, with broader reach through clinical development and licensing relationships. For FY2024, EyePoint reported revenue of #N/A, though the more important lens for understanding the company is its progress toward becoming a durable-retinal-therapy developer rather than its current sales base.

EyePoint at a Glance

Logo
Common name	EyePoint
Full legal name	EyePoint Pharmaceuticals, Inc.
Headquarters	Watertown, Massachusetts, USA
Ownership	Public company
Ticker	EYPT
Exchange	NASDAQ
Market Cap	$1.21B
Revenue (FY2024)	#N/A
Founding / major historical milestones	Founded in 1987; developed long-duration ocular drug-delivery technologies under its earlier pSivida identity; renamed EyePoint Pharmaceuticals in 2018; received U.S. Food and Drug Administration approvals for DEXYCU and YUTIQ in 2018; increasingly pivoted in the 2020s toward retinal pipeline development centered on DURAVYU.
Industry or industries	Biotechnology; ophthalmology; retinal therapeutics; sustained ocular drug delivery
Key products or services	DURAVYU (investigational); legacy ophthalmic products and related licensing economics including YUTIQ and DEXYCU; sustained-release ocular drug-delivery platform capabilities
Geographic footprint	Primarily United States, with clinical-development and partner-linked reach beyond the U.S.
Business segments as officially reported	One operating and reportable segment
Company website	https://www.eyepointpharma.com/

1. What Is the Strategy of EyePoint?

1a. What is the winning aspiration of EyePoint?

EyePoint’s winning aspiration is to become a meaningful retinal-disease company by developing long-acting therapies that reduce treatment burden without giving up the efficacy standards retina specialists expect. In public materials, management has framed the company around durable retinal treatment, especially in wet AMD and DME, where current standards of care often require frequent anti-vascular endothelial growth factor (anti-VEGF) injections and repeated office visits.

EyePoint has not generally emphasized near-term revenue or margin targets the way a mature pharmaceutical company would. Its public ambition is more clinical and strategic: move an investigational asset into late-stage development, prove durability at meaningful treatment intervals, and build a company around a retinal platform rather than a single short-lived commercial product.
1b. Where does EyePoint play?

EyePoint plays in ophthalmology, but in a deliberately narrow part of ophthalmology: chronic retinal disease managed by specialists. Its main target indications are wet AMD and DME, two large markets with clear unmet need around treatment burden. The company does not appear to be trying to cover every eye-care category; it is concentrating on diseases where sustained intraocular drug delivery could create a strong clinical and commercial advantage.

Geographically, EyePoint is centered on the United States. Commercially, the likely focus is the retina-specialist channel, supported by reimbursement and payer access work, with ex-U.S. opportunities more likely to be addressed through partnerships than through a large direct global commercial buildout.
1c. How does EyePoint plan to win?

EyePoint’s planned path to winning is differentiation through durability. Rather than competing head-to-head as another frequently injected retinal therapy, the company is trying to offer an investigational treatment that can maintain disease control for longer periods. DURAVYU, which uses vorolanib, a tyrosine kinase inhibitor (TKI), is the clearest expression of that strategy.

If EyePoint succeeds, its value proposition would be straightforward: fewer injections, fewer treatment visits, and a better fit for physicians and patients who struggle with the burden of chronic retinal therapy. That is a different basis of competition from pure price competition. It also means EyePoint must show not just that the drug works, but that the delivery system, safety profile, and retreatment interval create a practical advantage over incumbent anti-VEGF products, refillable implants, gene-therapy approaches, and low-cost substitutes such as off-label bevacizumab.
1d. What capabilities must EyePoint have in place?

To execute this strategy, EyePoint needs a fairly specific set of capabilities:
- Retinal clinical-development expertise, including study design against specialist standards of care.
- Drug-delivery science and formulation know-how for sustained intraocular therapy.
- Sterile manufacturing, chemistry, manufacturing, and controls (CMC), and quality systems suitable for late-stage ophthalmic products.
- Regulatory capability with the U.S. Food and Drug Administration (FDA) and other agencies.
- Deep relationships with retina specialists, investigators, and key opinion leaders.
- Capital-markets access and financial discipline, because the company is funding expensive development steps before material product revenue exists.
These are not generic biotech requirements; they are especially important in ophthalmology, where the prescriber base is concentrated and where delivery, procedure logistics, and safety perceptions matter heavily.
1e. What management systems does EyePoint require?

EyePoint needs management systems that are milestone-driven and cash-aware. In practice, that means portfolio governance around trial initiation, enrollment, readouts, CMC readiness, and regulatory interactions. Because EyePoint is not a diversified pharma company, management must also make disciplined resource-allocation decisions: one lead program can dominate spending, timeline risk, and investor perception.

The company also needs strong quality management, pharmacovigilance, external-vendor oversight, and program-management systems. For a business like EyePoint, strategy is less about broad annual operating plans and more about hitting a sequence of de-risking milestones while keeping enough capital and organizational capacity to reach the next one.

2. What Are the Current Strategic Initiatives of EyePoint?

Based on recent company communications, EyePoint’s current strategic agenda is tightly concentrated rather than spread across many unrelated priorities.

Advance DURAVYU in wet AMD. The top priority has been to move DURAVYU, EyePoint’s lead investigational retinal program, through the clinical path required for late-stage development and potential registration. Public updates have emphasized durability data, regulatory planning, and the work needed to support a pivotal development program.
Expand the same asset into DME. EyePoint has also prioritized DME as a second major indication. That is strategically important because it allows the company to use one delivery platform and one core molecule across multiple large retinal markets.
Build late-stage manufacturing and quality readiness. For a sustained-delivery ophthalmic product, clinical success alone is not enough. EyePoint has needed to invest in process robustness, product supply, release testing, and broader CMC readiness as it transitions from early development toward later-stage execution.
Concentrate the company around retinal innovation rather than a broad legacy commercial portfolio. Management has increasingly treated older commercial assets as monetizable or partner-managed economics, not the center of the corporate story. That helps keep operating attention on pipeline value creation.
Preserve financial flexibility. Like most development-stage biotechs, EyePoint has had to balance clinical ambition with runway management. Public messaging has emphasized funding strategy, disciplined spending, and keeping enough capital to reach major data and development milestones.
Position for eventual specialist commercialization or partnership. Even before approval, EyePoint has to think about how a durable retinal product would be priced, reimbursed, distributed, and sold into the concentrated retina-specialist market. That commercialization planning appears to be a medium-term initiative rather than a near-term broad sales buildout.

3. What Is the Business Model of EyePoint?

EyePoint’s business model is best understood as a development-stage specialty-biopharma model with legacy licensing and royalty economics in the background. The company is no longer best described as a scaled commercial ophthalmology company.

What customers actually buy today: today’s economic counterparties do not mainly buy a broad lineup of internally promoted products from EyePoint. Instead, EyePoint’s current revenue base appears to come largely from license-related, royalty, or other legacy-product economics tied to earlier ophthalmic assets. That makes current revenue a weak indicator of the company’s long-term value.

What customers would buy in the intended future model: if DURAVYU reaches the market, retina specialists and their practices would effectively buy a reimbursable, office-administered long-duration retinal therapy. Patients are the clinical beneficiaries, but the immediate commercial interface would be physicians, their practices, specialty distributors, and payers under the medical benefit.

Recurring versus one-time economics: retinal disease is inherently repeat-driven. Even a long-acting therapy aims to create recurring treatment episodes over time, just at a lower frequency than monthly or every-other-month injections. Current collaboration or royalty revenue can be lumpy; a successful retinal therapy would be more repeat-based.

Pricing power: true pricing power would depend on data. If EyePoint can show strong vision outcomes with materially lower treatment burden, it could support premium or at least well-defended reimbursement positioning. But pricing power would still be constrained by powerful benchmarks: Regeneron’s EYLEA franchise, Roche’s Vabysmo and Susvimo, and low-cost off-label bevacizumab.

Why business mix matters: EyePoint is highly concentrated. The company’s economics and valuation are driven far more by one lead retinal asset than by a diversified portfolio of approved products. That creates upside if the lead program works, but also concentration risk.

What drives margin and cash generation: gross margin is not yet the central metric because EyePoint is not operating at scale with a broad marketed portfolio. Today, operating losses are driven primarily by research and development, manufacturing readiness, and public-company overhead. Cash generation depends more on financing, partner receipts, and expense discipline than on internal product profits. If EyePoint commercializes a successful retinal therapy, long-term gross margins could be attractive, but they would depend on manufacturing yield, sterile-production efficiency, distribution economics, and reimbursement deductions.

Revenue model: today the model is largely collaboration-, licensing-, and royalty-influenced; in the future it would likely be a specialty-pharma model built around physician-administered, reimbursed retinal therapy with recurring retreatment demand.

4. What Products and/or Services Does EyePoint Sell?

EyePoint’s offering mix has two layers: a high-priority retinal pipeline and a set of legacy ophthalmic products and related economics.

DURAVYU (investigational). Formerly known as EYP-1901, DURAVYU is EyePoint’s lead strategic asset. It is an investigational sustained-delivery intravitreal therapy using vorolanib, a TKI, and is being developed for wet AMD and DME. By strategic importance, this is the company’s most important product candidate.
YUTIQ. YUTIQ is a corticosteroid intravitreal implant approved for chronic non-infectious uveitis affecting the posterior segment of the eye. It is part of EyePoint’s commercial history, but it appears far less central to the company’s forward strategy than DURAVYU.
DEXYCU. DEXYCU is an intraocular corticosteroid for postoperative inflammation associated with ocular surgery. As with YUTIQ, it is better understood as a legacy or monetized commercial asset than as the company’s main growth engine today.
Drug-delivery platform capability. EyePoint’s underlying strategic asset is not just a single drug candidate, but its sustained ocular drug-delivery know-how. In practice, that platform capability is part of what the company is building and what partners, investors, and potential acquirers may value.

The most important distinction is between legacy products and current growth assets. Legacy products helped establish EyePoint’s ophthalmology presence and generated economics, but the company’s forward narrative is built around DURAVYU and retinal pipeline execution.

5. What Are the Key Competitors or Peers of EyePoint?

EyePoint competes less with companies that look exactly like it and more with the products, platforms, and modalities that define retinal treatment. The most relevant competitors and peers include the following:

Regeneron Pharmaceuticals. Regeneron’s EYLEA franchise is one of the central standards of care in wet AMD and DME. It is a direct benchmark for efficacy, dosing interval, physician familiarity, and reimbursement.
Roche / Genentech. Roche’s retinal portfolio, including Vabysmo and Susvimo, is highly relevant to EyePoint because it competes on both efficacy and durability. Susvimo is especially important as another approach to reducing injection burden.
Ocular Therapeutix. Ocular Therapeutix is a close biotech peer because it is also pursuing long-duration retinal drug delivery. It is one of the more useful comparables for investors evaluating durable-retina strategies.
AbbVie. Through its ophthalmology portfolio, including steroid-based retinal therapies, AbbVie is a meaningful ophthalmic competitor, though not always in the exact same product class.
Adverum Biotechnologies. Adverum represents a different durability model: gene therapy intended to reduce the frequency of ongoing injections in retinal disease.
REGENXBIO. REGENXBIO is relevant as another durability-oriented retinal developer using gene therapy rather than an implant-based drug-delivery system.
Kodiak Sciences. Kodiak is a retinal-disease biotech peer focused on longer-acting approaches and therefore belongs in the competitive set even if programs and clinical trajectories differ.
Bayer. Bayer’s role in the global EYLEA franchise makes it an important ex-U.S. competitive reference point in retinal disease.

In addition to named companies, off-label bevacizumab is an important substitute. It is not a corporate peer in the usual sense, but it is strategically important because it can anchor payer and physician perceptions around price and treatment economics.

6. What Is the Marketing Strategy of EyePoint?

At this stage, EyePoint’s marketing strategy is more scientific and specialist-oriented than consumer-oriented. Because the company’s lead asset is investigational, the immediate marketing equivalent is really clinical communication: investigator engagement, scientific congress visibility, peer-to-peer education, and credibility with retina specialists.

Historically, legacy products such as YUTIQ and DEXYCU required focused specialty promotion rather than broad mass-market advertising. Looking forward, if DURAVYU is approved, EyePoint’s likely marketing model would center on a targeted retina-specialist message built around durability, clinical outcomes, ease of use, and reimbursement support. That would likely involve:

Medical education and congress presence.
Key opinion leader development and peer influence.
Health-economic and reimbursement messaging for payers and physician offices.
Practice-level support rather than mass direct-to-consumer advertising.

So marketing does matter, but it does not appear to be EyePoint’s primary differentiator today. Clinical data and delivery technology are the main differentiators; marketing is the support system that would help convert those advantages into adoption.

7. What Are the Key Customer Segments of EyePoint?

EyePoint’s customer structure is unusual because the company is in transition from legacy commercial activity to pipeline-led value creation. The key customer segments therefore include both current economic counterparties and intended future end markets.

Retina specialists and ophthalmologists. These are the most important eventual prescribers for DURAVYU and the most strategically important physician audience for EyePoint overall.
Patients with chronic retinal disease. The main patient groups are people with wet AMD and DME. Wet AMD skews older; DME reflects diabetes-related eye disease and can involve a somewhat different patient journey.
Payers and reimbursement decision-makers. For physician-administered retinal therapies, reimbursement dynamics are critical. Medicare and commercial payers strongly influence adoption and realized economics.
Licensees, distributors, and commercial partners. For legacy products and monetized assets, partners can be more important than end customers from a revenue-recognition perspective.
Clinical investigators and trial sites. In a development-stage biotech, trial sites are not customers in the usual sense, but they are mission-critical stakeholders in the path to value creation.

EyePoint is therefore highly concentrated around a specialized market rather than broadly diversified across many customer groups. That concentration can be an advantage if the company wins with retina specialists, but it also means missteps in one specialist channel matter a great deal.

8. What Is the Sales Model of EyePoint?

Today, EyePoint’s sales model appears limited relative to a mature commercial pharmaceutical company because the lead asset is still investigational and legacy products have become less central or more partner-managed. Historically, the company used a focused specialty-sales approach appropriate for ophthalmology rather than a large primary-care model.

If DURAVYU reaches commercialization, the likely sales model would be a specialist, high-touch, concentrated-field model:

Direct engagement with retina specialists and high-volume retina practices.
Distribution through specialty pharmaceutical channels suited to physician-administered products.
Strong reimbursement support, patient-access services, and buy-and-bill economics.
Potential ex-U.S. partnering rather than building a global direct sales infrastructure from scratch.

This channel structure matters strategically. A concentrated prescriber base means EyePoint would not need a massive field force, but it would need excellent account prioritization, territory design, reimbursement support, and physician trust. That tends to create fertile ground for discrete consulting projects in launch planning, market access, and commercial model design.

9. In What Geographies Does EyePoint Operate?

EyePoint is primarily a U.S.-centered company. Its headquarters are in Watertown, Massachusetts, and the center of gravity of management, strategy, and corporate operations is in the United States. Its development activities, quality work, and manufacturing oversight also appear to be U.S.-led, even where external partners support execution.

Commercially, the company does not currently resemble a large multinational pharma company with an extensive direct global sales footprint. Instead, its reach beyond the United States comes mainly through:

Clinical-development activity that can involve sites beyond the U.S.
Licensing and partner relationships tied to legacy ophthalmic assets.
Potential future partnering options for markets outside the U.S.

That means EyePoint is operationally concentrated rather than geographically diversified. For now, that is consistent with its stage of development and capital discipline.

10. Who Are the Owners of EyePoint?

EyePoint is a publicly traded company listed under the ticker EYPT. As a small-cap biotech, its ownership is primarily institutional and market-based rather than family-controlled or government-controlled.

In its recent public filings, EyePoint has not been characterized as having a controlling shareholder. Ownership can shift meaningfully over time because biotech companies often issue equity to fund development, and specialist healthcare funds can build or reduce positions around clinical milestones.

11. How Is EyePoint Organized?

Officially, EyePoint reports one operating and reportable segment. Practically, however, the company can be understood as a set of functional groups organized around a concentrated retinal strategy:

Research and development. Clinical development, preclinical work, medical strategy, and pipeline planning.
Technical operations. CMC, manufacturing oversight, quality, and supply planning for ophthalmic drug-delivery products.
Regulatory and medical affairs. FDA interactions, safety, compliance, and scientific communication.
Legacy product and partner management. Oversight of monetized or partner-linked commercial assets.
Corporate functions. Finance, legal, investor relations, and public-company administration.

The most important organizational fact is that EyePoint is not a diversified multi-division pharmaceutical company. Resource allocation is dominated by its lead retinal program and the capabilities needed to support it.

12. How Does EyePoint Operate?

On a day-to-day basis, EyePoint operates like a focused ophthalmology biotech. The company creates value by moving retinal programs through the development chain while maintaining the technical systems needed for a sterile, sustained-delivery product.

Its operating model includes the following activities:

Designing and running retinal clinical studies.
Managing investigator sites, contract research organizations, and data collection.
Developing and controlling the manufacturing process for intraocular drug-delivery products.
Handling quality assurance, release testing, and regulatory documentation.
Maintaining intellectual property around drug delivery and product design.
Managing legacy product economics and external commercial relationships.

The main operational complexities are not the same as those of a broad commercial drug company. EyePoint’s bottlenecks are more likely to involve enrollment pace, clinical endpoints such as vision and anatomical outcomes, sterile-manufacturing consistency, and the coordination required to support late-stage development on limited resources.

13. What Are the Growth Opportunities for EyePoint?

EyePoint’s growth opportunities are substantial, but they are tightly linked to clinical execution.

Successful development of DURAVYU in wet AMD. This is the largest opportunity by far. A durable therapy in wet AMD could support significant commercial value if efficacy and safety are competitive.
Expansion into DME. Using the same core platform in a second large retinal indication is one of the clearest ways to multiply the value of the lead asset.
Additional retinal indications. If the platform continues to work, EyePoint could reasonably expand into adjacent retinal diseases where treatment burden remains a problem.
Ex-U.S. partnerships. Because EyePoint is U.S.-centered, partnering outside the U.S. could provide capital, commercialization reach, or both.
Platform extension. The company’s broader opportunity is not only one product candidate, but the ability to apply sustained ocular delivery to other molecules or mechanisms.
Strategic transactions. If data are compelling, EyePoint could become a more attractive partner or acquisition candidate for a larger ophthalmology or biopharma company. That is an external inference, not a stated company commitment.

The main constraints are equally clear: clinical-trial risk, regulatory risk, manufacturing scale-up risk, intense competition from established retinal franchises, reimbursement pressure, and the ongoing need to fund development before significant internal product revenue exists.

14. What Is the History of EyePoint?

1987: The company’s roots trace back to 1987, when it was founded under the pSivida identity.
2000s and 2010s: The business developed a reputation around ocular drug-delivery technology and built experience in sustained-release ophthalmic therapeutics.
2018: The company changed its name to EyePoint Pharmaceuticals, marking a clearer ophthalmology-focused corporate identity. In the same year, the FDA approved DEXYCU and YUTIQ, giving the company a more visible commercial presence in ophthalmology.
2020s: EyePoint increasingly shifted from a small commercial ophthalmology model to a more focused retinal-development model. Legacy products became less central, while management prioritized capital and attention toward the retinal pipeline.
Recent period: DURAVYU emerged as the lead strategic asset, and the company’s narrative became centered on durable retinal therapy, late-stage development planning, and the transition from legacy-product economics to pipeline-led value creation.

15. What Is the Technology Strategy of EyePoint?

EyePoint’s technology strategy is one of the clearest ways to understand the company. Rather than trying to win solely by discovering entirely new retinal biology, EyePoint is using drug-delivery technology to improve how known or validated mechanisms are delivered inside the eye.

The company’s core technological idea is that durable local delivery can change the competitive equation in retinal disease. That means the platform is not just an internal enabler; it is a core part of the product proposition. In EyePoint’s case, the delivery system is central to why a physician might choose the therapy at all.

This is strategically important for three reasons:

It differentiates EyePoint against therapies that work but require frequent injections.
It allows the company to build a platform logic across multiple retinal indications.
It creates a basis for future partnering or asset expansion beyond one molecule.

In short, EyePoint appears to be pursuing a platform-plus-asset strategy, with delivery technology acting as the bridge between clinical need and commercial differentiation.

16. What Is the R&D Strategy of EyePoint?

EyePoint’s research and development strategy appears focused, capital conscious, and indication selective. The company is not trying to run a broad discovery engine across many therapeutic areas. Instead, it is concentrating R&D on retinal diseases where the unmet need is clear, trial endpoints are clinically meaningful, and a durable-delivery advantage could matter.

Several principles seem to define that strategy:

Focus on validated disease biology. EyePoint is not betting only on unproven mechanisms; it is trying to improve treatment delivery and durability in diseases where efficacy benchmarks are already well understood.
Use sequential indication expansion. Wet AMD is the flagship opportunity, with DME as an important follow-on use case for the same core program.
De-risk through staged clinical development. The company’s path has involved using earlier studies to establish durability signals before committing to broader late-stage investment.
Develop CMC in parallel with clinical progress. For an ophthalmic sustained-delivery product, manufacturing readiness is part of R&D strategy, not a separate afterthought.

That is a disciplined approach for a company of EyePoint’s scale. It reduces strategic sprawl, but it also increases dependence on one lead program.

17. What Is the Finance Strategy of EyePoint?

EyePoint’s finance strategy is typical of a development-stage biotech, but with an added layer of portfolio concentration. The company needs to fund expensive retinal development while maintaining enough balance-sheet flexibility to survive delays, expand trials, and build late-stage manufacturing capability.

At a high level, the finance strategy appears to include:

Prioritizing cash runway over near-term profitability. The company is investing ahead of revenue, so liquidity and runway are more important than current earnings.
Using equity markets as a core funding source. That is common in biotech and likely to remain true until a major product reaches commercialization or a partnership provides substantial non-dilutive capital.
Keeping commercial overhead relatively restrained. Because EyePoint has moved away from a broad internally promoted legacy-product model, it can focus spending on R&D, CMC, and targeted readiness work.
Using legacy asset economics as supplemental support rather than a core growth engine. Royalties, licenses, or other monetized-product economics can help, but they do not replace the need to finance the lead program properly.

Finance strategy therefore supports corporate strategy in a direct way: preserve enough capital to get DURAVYU and related retinal programs through major value-inflection points.

18. How Does the Supply Chain of EyePoint Function?

EyePoint’s supply chain is important because its products and product candidates are specialized ophthalmic therapies, not standard oral solid-dose drugs. The supply chain must support sterile manufacturing, precise drug-device handling, quality release, and dependable clinical-site or commercial-site delivery.

The key supply-chain activities likely include:

Sourcing active pharmaceutical ingredient and specialized formulation inputs.
Manufacturing or overseeing the manufacture of sustained-delivery ophthalmic inserts.
Aseptic processing, quality assurance, and lot release testing.
Packaging and shipping product to clinical sites or commercial channels.
Coordinating inventory with trial enrollment or specialist-demand patterns.

Specific suppliers do not appear to be a major public part of the company story, but supplier reliability still matters strategically. In retinal development, an unreliable supply chain can delay enrollment, complicate site logistics, and undermine launch readiness. EyePoint therefore appears to need a hybrid model: strong internal technical oversight combined with disciplined use of external manufacturing and supply partners.

19. How Companies Like EyePoint Leverage Independent Consultants through Umbrex

Companies like EyePoint use independent consultants when they need highly specialized strategic or operational help without hiring a full consulting team or building permanent overhead too early. Umbrex has grown a global community of over 8,000 independent management consultants based in more than 50 countries. These consultants include alumni of McKinsey, Bain, BCG, and other top firms, and they work across Strategy, Operations, Organization, Marketing, Sales, Finance, Technology, ERP, and AI. For a company like EyePoint, that model fits especially well during periods of concentrated clinical, manufacturing, and commercialization decision-making.

Pivotal program PMO support: building a milestone-based program management office for late-stage wet AMD and DME development, including governance, risk tracking, and cross-functional decision cadence.
Launch-readiness planning: designing the commercialization blueprint for a future retina-specialist launch, including target-account segmentation, territory design, and field-force sizing.
Pricing and market-access strategy: developing reimbursement scenarios, payer messaging, and buy-and-bill economics for a durable retinal therapy competing against EYLEA, Vabysmo, Susvimo, and off-label bevacizumab.
Ex-U.S. partnering strategy: screening target geographies, identifying potential licensing partners, and preparing partner materials for regions where EyePoint may prefer a partnership model.
Clinical-to-commercial demand forecasting: building scenario-based models that connect trial outcomes, label assumptions, dosing intervals, and prescriber adoption curves to revenue and capital planning.
Manufacturing and CMC scale-up support: helping management prioritize technical-operations investments, external-vendor strategy, and supply-chain risk mitigation ahead of late-stage development or launch.
Portfolio prioritization: evaluating which retinal indications, lifecycle opportunities, or platform extensions deserve capital first and which should wait.
Organization design for transition: defining the right structure as EyePoint moves from a clinical-stage company toward a commercial-stage specialty ophthalmology company.
Retina-customer insight work: mapping retina-practice workflows, referral patterns, physician objections, and patient-burden pain points to sharpen the eventual product value proposition.
Business development diligence: supporting due diligence on in-licensing, co-development, or strategic transaction opportunities in retinal disease and ophthalmic drug delivery.

EyePoint Strategy and Business Model